Recent studies have shown that people with leukemia may not enjoy optimum protection after vaccination against the emerging coronavirus.
The American Society of Hematology reported that two new studies showed that the Moderna vaccine is less effective in patients with chronic lymphocytic leukemia (CLL) and multiple myeloma, two types of leukemia.
The first study reported that people with chronic lymphocytic leukemia had significantly lower immune response rates to two doses of the vaccine compared to healthy people.
The study was conducted on 167 patients with CLL, and only four out of 10 patients (39.5%) had a positive response.
The study revealed that people with this type of cancer have different immune responses to the vaccine.
Overall, the response rate to the vaccine was significantly lower than what we see in the general population, the study adds.
The research revealed wide differences in the immune response between patients with CLL and the stages of the cancer treatment process.
Similar results were found in elderly patients with multiple myeloma.
In a study published Friday, researchers reported similar results after the first dose of the same vaccine in elderly patients with multiple myeloma.
Evangelos Terbus of the National and Kapodistrian University of Athens, Greece, and colleagues compared 48 patients with multiple myeloma at the Alexandra Hospital in Athens.
The average age of all participants was 83 years. On day 22, after the first dose of the vaccine and before the second dose, the average response was only 20.6%.
The new studies come to double the suffering of cancer patients from Corona in general, as the World Health Organization in Europe expressed Thursday, its regret for the impact of the Covid-19 epidemic on cancer treatment, considering it “catastrophic.” And she noted that cancer treatment services have stopped in a third of the countries in her region.